Joint Formulary & PAD

Haloperidol - Schizophrenia and other psychoses

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Oral solution
  • Tablets
Associated Icons :
SPC
Restrictions / Comments :
Important

Off-label use.

Initiation by a SABP specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.

 

Status 2

Blue
Formulations :
  • Capsules
Associated Icons :
SPC
Restrictions / Comments :
Important

Capsules are an unlicensed product.

Initiation by a SABP specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.

 

Status 3

Amber
Formulations :
  • Depot injection
Associated Icons :
SPC
Restrictions / Comments :
Important

Haloperidol decanoate - administration under the shared-care LCS when prescribed in Primary Care.

See shared care document below

Documents :
 
 

Status 4

Red
Formulations :
  • Depot injection
Associated Icons :
SPC
Restrictions / Comments :
Important

Haloperidol decanoate - where there is no LCS in place, the prescribing responsibility remains with SABP.

Secondary Care may prescribe for in-patients (on the instruction of a SABP specialist) and prescribing continued by SABP after discharge.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Haloperidol
Indication :
Schizophrenia and other psychoses
Group Name :
Keywords :
depot antipsychotics, antipsychotic depot injections, LAI
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Traffic Light Entries :
4

Committee Recommendations (1)

The Surrey Heartlands APC recommends the administration of depot antipsychotic injections under an AMBER shared care agreement for practices that have signed up to the agreed locally commissioned service (LCS).
The updated shared care agreement can be found below.

Surrey Heartlands CCG have developed the LCS to enable stable patients with schizophrenia to be prescribed and administered these injections through their primary care prescriber (GP). 

If a practice has not signed up to the LCS the drug remains as RED status and prescriptions will be issued by the provider.